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Abstract
Background: Liver cancr is a heterogeneous disease in terms of etiology, biologic and clinical behavior.
Very little is known about how many genes concur at the molecular level of tumor development,
progression and aggressiveness. To explore the key genes involved in the development of liver cancer, we
established a rat model induced by diethylnitrosamine to investigate the gene expression profiles of liver
tissues during the transition to cirrhosis and carcinoma.
Methods: A rat model of liver cancer induced by diethylnitrosamine was established. The cirrhotic tissue,
the dysplasia nodules, the early cancerous nodules and the cancerous nodules from the rats with lung
metastasis were chosen to compare with liver tissu e  o f  n o r m a l  r a t s  t o  i n vestigate the differential
expression genes between them. Affymetrix GeneChip Rat 230 2.0 arrays were used throughout. The
real-time quantity PCR was used to verify the expression of some differential expression genes in tissues.
Results: The pathological changes that occurred in the livers of diethylnitrosamine-treated rats included
non-specific injury, fibrosis and cirrhosis, dysplastic nodules, early cancerous nodules and metastasis.
There are 349 upregulated and 345 downregulated genes sharing among the above chosen tissues when
compared with liver tissue of normal rats. The deregulated genes play various roles in diverse processes
such as metabolism, transport, cell proliferation, apoptosis, cell adhesion, angiogenesis and so on. Among
which, 41 upregulated and 27 downregulated genes are associated with inflammatory response, immune
response and oxidative stress. Twenty-four genes associated with glutathione metabolism majorly
participating oxidative stress were deregulated in the development of liver cancer. There were 19
members belong to CYP450 family downregulated, except CYP2C40 upregulated.
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Conclusion: In this study, we provide the global gene expression profiles during the development and
progression of liver cancer in rats. The data obtained from the gene expression profiles will allow us to
acquire insights into the molecular mechanisms of hepatocarcinogenesis and identify specific genes (or
gene products) that can be used for early molecular diagnosis, risk analysis, prognosis prediction, and
development of new therapies.
Background
HCC is a heterogeneous disease in terms of etiology, bio-
logic and clinical behavior. Meanwhile, hepatocarcino-
genesis is a long-term, multistep process associated with
changes in gene expression profiles. In the last several
years, there have been important gains in our understand-
ing of the pathogenesis of HCC and our appreciation of
the critical oncogenic and tumor suppressor pathways
involved in hepatocarcinogenesis [1-5]. Despite this, cur-
rent knowledge about the molecular pathogenesis of HCC
is a result of investigations of fully developed HCC. Very
little is known about how many genes concur at the
molecular level of tumor development, progression and
aggressiveness.
Molecular profiling has been successfully used to identify
candidate genes for HCC in human and animal model
systems[3]. Although many approaches (including
genome-scale studies) provide insights into some of the
stages in human tumorigenesis, a sequential analysis of
the development of tumors in humans is very difficult.
Most of them have not given us the gene expression pro-
files that could point to those genes that play key roles
during the whole carcinogenetic process from initiation to
metastasis. Animal models of carcinogenesis have permit-
ted the examination of the stages of neoplastic develop-
ment in considerable detail.
In this study, we established the rat model of liver cancer
induced by DEN to explore the processes of initiation and
progression of HCC[6]. HCC develops commonly, but
not exclusively, in a setting of chronic liver cell injury,
which leads to inflammation, hepatocyte regeneration,
liver matrix remodeling, fibrosis, and ultimately, cirrho-
sis[7,8]. The histological changes in DEN-induced liver
cancer in rats are similar to those seen in human HCC. We
think the similar phenotype might be based on similar
gene expression profiles. Affymetrix GeneChip Rat 230
2.0 arrays were used to analyze gene expression profiles of
liver tissues from control and DEN-treated rats during the
process from cirrhosis to metastasis. This allowed us to
obtain an almost complete picture of the early genetic
alterations that are directly or indirectly involved in the
development of HCC. We supposed that the genes expres-
sion profiles deregulated during the process from liver cir-
rhosis to carcinoma and metastasis play key roles in the
hepatocarcinogenesis. The data obtained from the gene
expression profiles will allow us to acquire insights into
the molecular mechanisms of hepatocarcinogenesis and
identify specific genes (or gene products) that can be used
for early molecular diagnosis, risk analysis, prognosis pre-
diction, and development of new therapies.
Materials and methods
Animals and treatments
Male Wistar rats weighing 120–150 g at the beginning of
the experiments were obtained from SLAC Laboratory
Animal Co. Ltd. (Shanghai). The animals were acclima-
tized to standard laboratory conditions (temperature 22–
25°C, relative humidity 50–60%, and 12 hour photoperi-
ods (lights on 07:00–19:00 h)) and were housed in stain-
less steel wire-mesh cages (five rats per cage). During the
entire period of study, the rats were supplied with a semi-
purified basal diet (Shanghai) and water ad lib. All exper-
iments followed the Guide for the Care and Use of Labo-
ratory Animals.
Briefly, ninety Wistar rats were randomly divided into two
groups: the control and DEN group (DEN, Sigma Chemi-
cal Co. St Louis, MO; CAS 56-23-5; purity > 98%). After
one week on a basal diet, rats belonging to the DEN group
underwent intragastric administration of 1% aqueous
solution of DEN (70 mg/kg) once a week, consecutively
for 14 weeks. Animals that belonged to the control group
received distilled water. There were ten rats in the control
group. Daily food and water intakes were noted and the
body weights of the animals from each group were
recorded every second day. The rats were sacrificed with
25% (g/ml) urethane anesthesia (6 ml/kg) by intraperito-
neal injection and sacrificed at different time points. At
the end of the 2nd, 4th and 6th week after DEN-treatment,
3, 3, and 4 rats were sacrificed respectively at these time
periods. From the end of the 8th week until the end of the
20th week after DEN-treatment, ten rats were sacrificed
respectively every two weeks. Meanwhile one age-
matched control rat was sacrificed. All the age-matched
rats from the control group and rats of treatment groups
were sacrificed on the same day.
Sample collection and histopathological analyses
Animals were chosen sequentially for necropsy. The entire
liver was observed grossly and weighted. The selected liver
tissues were observed for gross changes, divided into
pieces of about 0.1 g, snap-frozen directly in liquid nitro-Journal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
Page 3 of 16
(page number not for citation purposes)
gen and stored at -80°C prior to RNA isolation for micro-
array analysis. The remaining livers were preserved in 10%
phosphate-buffered formalin. The liver tissue fixed in
neutral formalin was embedded in paraffin, sectioned,
and stained with hematoxylin and eosin (H&E). His-
topathologic examinations of the liver sections were con-
ducted by a pathologist and peer-reviewed.
RNA extraction
Frozen liver sections were ground in a Mixer Mill mm 200
(Retsch GmbH and Co. KG, Haan, Germany) using pre-
cooled stainless steel balls. Total RNAs were isolated from
livers with Trizol Reagent (Invitrogen, CA) using manu-
facturer recommended procedures. The ratio of the optical
densities from RNA samples measured at 260 and 280 nm
was used to evaluate nucleic acid purity, and total RNA
concentrations were determined by the absorbance at 260
nm. The quality of total RNA was estimated based on the
integrity of 28S and 18S rRNA. RNA was separated using
1% agarose gel electrophoresis. Good RNA quality was
indicated by 28S rRNA banding having twice the intensity
of the 18S rRNA, without significant smearing of the rRNA
bands. Samples of total RNA from livers of rats from the
same time points were pooled for subsequent use in the
GeneChip analysis. Prior to GeneChip analysis, the
pooled total RNA samples were purified using the RNeasy
Total RNA Mini Kit (Qiagen, Valencia, CA) according to
manufacturer's instructions.
Oligo microarray hybridization
Biotin-labeled cRNA samples were used for hybridization
of Affymetrix GeneChip Rat 230 2.0 arrays. The arrays
were prepared according to the protocol supplied with the
GeneChip Sample Cleanup module (P/N 900371,
Affymetrix Inc., Santa Clara, CA). Briefly, 5 μg total RNA
was used for cDNA synthesis with the SuperScript Choice
System (Invitrogen Life Technologies, Carlsbad, CA)
employing a T7-(d7)24 primer. After spin column purifica-
tion, biotin-labeled cRNA was synthesized from the cDNA
using the ENZO RNA Transcript Labeling Kit (Affymetrix
Inc.). Spin column-purified cRNA was quality controlled
using an Agilent 2100 Bioanalyzer and spectrophotomet-
rically quantified. The cRNA (15 μg) was then fragmented
in buffer supplied with the Cleanup Module and hybrid-
ized for 16 h at 45°C (Affymetrix Genechip Hybridization
Oven 640). The microarrays were washed and stained
with streptavidin-phycoerythrin (SAPE, Molecular
Probes) on the Affymetrix Fluidics Station 450, including
an amplification step according to the manufacturer's
instructions. Fluorescent images were read using the Gene
Array Scanner 3000. The raw data image files (DAT) were
converted into RPT files using Affymetrix Microarray Suite
(MAS) 5.0. In RPT files, the scan data from the 36 pixels
per oligo set were averaged. Pooled RNAs of cirrhotic tis-
sue, the dysplasia nodules, the early cancerous nodules
and the cancerous nodules from the rats with lung metas-
tases at the 12th, 14th, 16th, and 20th week after DEN-treat-
ment and from normal control rat were processed,
hybridized and analyzed individually.
The chips were scanned in an Agilent ChipScanner to
detect hybridization signals. Average target intensity was
set at 500 arbitrary units. Each array was assessed for qual-
ity and stability by examining replicated copies of the
same gene at different locations on the array. To ensure
the quality of the cRNA samples and of the Affymetrix
GeneChips, quality control experiments were performed
using test chips, and the same cRNA sample used in both
the test chip and GeneChip.
Microarray quality control
With GeneChip Operating Software (GCOS) v1.2, dark
and white spots, gradients and distortions were detected
and corrected using the RPT file data. The GeneChip Rat
Genome 230 2.0 Array provides the entire transcribed rat
genome on a single array and enables scientists to obtain
the most comprehensive view of the transcribed rat
genome in order to make accurate biological conclusions.
The Affymetrix Rat Genome 230 2.0 microarrays contain
31,000 probe sets corresponding to about 24,000 anno-
tated rat genes and 6693 expressed sequence tags (ESTs).
Each probe set is represented by 11–20 pairs of 25 mer oli-
gonucleotides. Each probe pair consists of a perfect match
oligo (PM) complementary to the cRNA target sequence
and a mismatched oligo (MM). Using the MAS 5.0 statis-
tical algorithms implemented in the Quality Controller
software, the intensities of all 11–20 probe pairs were con-
densed to one intensity value per probe set associated
with a statistical detection p  value calculated from the
intensity differences of the PM and corresponding MM
oligos. This p value indicates how reliably a transcript is
detected. Transcripts with p < 0.04 were designated
present, whereas those with a p > 0.06 were designated
absent. Transcripts with 0.04 < p < 0.06 were designated
marginal, whose reliability were doubted and need to be
verified by methods with higher sensitivity. After condens-
ing (which also included overall microarray background
correction) the microarray was scaled to an average signal
intensity of 100, after excluding the highest and lowest
2% of the data. GeneChip Rat Genome 230 2.0 microar-
rays include a set of rat maintenance genes to facilitate the
normalization and scaling of array experiments. These
probe sets serve as a tool to normalize or scale data prior
to performing data comparison. These normalization
genes show consistent levels of expression over defined
sample sets.
Microarray data analysis
The microarray data were analyzed using the microarray
suite 5.0 software. First, using the present genes, those sig-Journal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
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nificantly deregulated between the DEN-treated and con-
trol groups were selected using a two-sample t-test with a
p cutoff value of 0.001 in combination with n-fold regu-
lation/ratio of means. This requires that the mean inten-
sity of a gene has to be at least n times different between
the treated and control sample group to be included. The
cutoff was set at 2 times.
Secondly, genes designated present in treated samples but
absent in controls, or vice versa, were determined, as these
could be genes induced from or repressed to background
expression levels, respectively, after treatment. From these
genes, those discriminating between treated and control
samples were again selected with a two-sample t-test (p <
0.001), combined with the requirement of an at least two-
fold difference of the mean intensities for a given gene.
Scatter plot, gene tree
Scatter plots were used to visually examine the expres-
sional level of genes between the control and DEN-
exposed groups. Hierarchical dendrograms were drawn
with the Cluster (2.0). It was created by clustering the
genes according to their expression in response to the car-
cinogenic agent. Genes sharing similar expression profiles
tended to be clustered together, and the location of a
branch containing the genes can be considered a measure
of how similar the gene expression was. Genes were
selected for the construction of gene tree if the expression
of the gene was two-fold greater or less in the treatments,
relative to that in the corresponding control. The horizon-
tal axis shows the clustering of the genes according to their
expression across treatments; while the vertical axis
showed the clustering according to their expression pro-
file in the treatment.
Statistical analysis
The genechip probe array system only allows comparison
of one treatment hybridizing with the probe set. In a com-
parison analysis, two samples were hybridized to two
genechip probe arrays of the same type, they were com-
pared against each other in order to detect and quantify
changes in gene expression. One genechip was for base-
line (control) and the other was for the experiment (treat-
ment). Two sets of algorithms were generated and they
were used to generate change significance and change
quantity metrics for every probe set using Microarray Suite
(MAS) version 5.0 (Affymetrix, CA). The change algo-
rithm generated a Change p value and an associated fold-
change value. The second algorithm gave a quantitative
estimate of the change in gene expression in the form of
Signal Log Ratio. In the present study, the level of gene
expression can be regarded as increased if its Change p-
value was less than 0.002 and the gene expression would
be considered to be decreased if its Change p-value was
greater than 0.997. This method has been used by other
investigators. Fold change could be calculated with the
following formula: fold change = 2(signal log ratio).
Validation of differential expression of genes by real-time 
RT-PCR
The differential expression of selected genes was further
validated by real-time PCR with SYBR green-based detec-
tion (ABI) using gene-specific primer pairs that were run
on an ABI 7000 fluorescent sequence detection system
(Perkin-Elmer, Foster City, CA). It is known that only the
cDNA of each target gene can be the template, owing to
the fact all the primer sequences span one or more introns
by design (Gene Runner). The rat housekeeping gene β-
actin was used as the control. Quantitative values were
obtained from the cycle number (Ct value) at which the
increase in fluorescent signal (associated with exponential
growth of PCR products) starts to be picked up by the laser
detector of the detection system. Results, expressed as N-
fold differences in target gene expression between the liver
tissues of DEN-treated and normal rats and termed 'Ntar-
get' were determined using the formula: Ntarget =
2ΔCtsample (while ΔCtsample = ΔCtDEN - ΔCtNormal), where the
ΔCtDEN and  ΔCtnormal values of the sample were deter-
mined by subtracting the Ct value of the target gene from
the average Ct value of the β-actin gene.
Results
Histopathology
The histological changes of livers of the DEN-treated rats
can be divided into three stages. Initially, from the 2nd to
8th week, non-specific injury occurred such as cellular
swelling, fatty changes, necrosis, inflammatory infiltra-
tion and hepatocyte regeneration. On the 10th to the 14th
week, significant liver fibrosis occurred. At the 10th week,
the livers showed an quantitative increase in connective
tissue, and encapsulation of regenerative nodules, while at
the end of the 12th week, nodular cirrhosis could be seen
macroscopically. At the 14th week, gray-white nodules, 3
mm to 5 mm in diameter, could be distinguished from the
surrounding reddish brown cirrhosis nodules in the livers
of 2/10 rats. These were histologically diagnosed as dys-
plastic nodules. From the 16th  to the 20th  week the
number of nodules increased significantly. At the 16th
week, nodules, 5 mm to 1.5 cm in diameter, could be dis-
tinguished in the livers of 8/10 rats, while at the 18th and
the 20th week, gray-white nodules were present in the liv-
ers of all 20 rats. In addition, by the 20th week, abdominal
cavity and lung metastases were observed in 2/10 rats.
(Figure 1, 2)
Isolation of RNA, microarray hybridization, scanning and 
signal detection
Liver tissues were taken from the control and the DEN-
treated rats. Total RNA was isolated from theses samples
and used to prepare cRNA probes for hybridization withJournal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
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Affymetrix GeneChip Rat 230 2.0 arrays (Figure 3). The
hybridized microarrays were then scanned and the signals
acquired (Figure 4). At the 12th  week, liver cirrhosis
occurred in 10 of 10 rats, so we took the pooled cirrhotic
tissues from the 10 rats for the microarrays. At the 14th
week, dysplastic nodules occurred only in the livers of 2/
10 rats, so we took the pooled dysplastic nodules from the
two rats for the microarrays. At the 16th week, early tumor
nodules occurred in the liver of 8/10 rats, so we took the
pooled tumor nodules from the eight rats for the microar-
rays. At the 20th week, tumor nodules occurred in all of the
ten rats(10/10), but lung metastasis only occurred in the
two of them, so we took the pooled tumor nodules in the
liver from the two rats with lung metastasis for the micro-
arrays. We used the pooled liver tissues from the control
rats killed at the 12th, 14th, 16th and the 20th week for the
microarrays. The decision to pool the mRNA from the rat
livers was made in order to obtain a representative analy-
sis of gene expression changes across more than one ani-
mal.
Analysis of the differential expression genes
The differential expression genes of cirrhotic tissue, dys-
plastic nodules, early tumors nodules and tumor nodules
from rats with lung metastasis compared with the tissue
from normal rats were screened and to determine the
upregulated and downregulated DEGs. The results are
shown in Table 1.
The upregulated and the downregulated DEGs of cirrhosis
tissue, dysplastic nodules, early tumor nodules and tumor
nodules with lung metastasis vs the normal livers respec-
tively were grouped into functional categories using gene
ontology (GO) terms (Table 2). The GO terms such as
metabolism, transport, cellular proliferation, apoptosis,
adhesion, angiogenesis, etc. were chosen. Meanwhile,
some other genes were associated with oxidative stress,
immune response and inflammatory response.
The histological changes during the hepatocarnogenesis
in DEN-treated rat models were similar to those seen in
humans, including non-specific damage, fibrosis, cirrho-
sis, dysplastic nodules, early tumorous nodules, progres-
sion and metastasis, which appeared to be sequential
events. The processes of chronic inflammation, fibrosis
and cirrhosis are closely related to liver cancer, while cir-
rhosis was considered as the precancerous lesions. There-
fore, the co-expression of deregulated genes among these
four stages might suggest they play key roles in the devel-
opment of hepatocellular carcinoma. Among upregulated
DEGs sharing from cirrhosis to metastasis, there were 246
known genes, 39 translocation loci, 51 inferred genes and
13 unkown genes; while among downregulated DEGs
sharing from cirrhosis to metastasis, there were 215
known genes, 48 translocation loci, 63 inferred genes and
19 unkown genes (see additional file 1).
The gross appearance of the livers from DEN-treated rats Figure 1
The gross appearance of the livers from DEN-treated 
rats. (A-B) The liver from the rat by DEN-treated at the 16th 
week (red arrows stick to early cancerous nodules(A); The 
metastasis mass in the abdominal cavity from the rat by 
DEN-treated at the 20th week (B).
A B 
The histological changes of livers from control and DEN- treated rats Figure 2
The histological changes of livers from control and 
DEN-treated rats. (A) the normal liver tissue from rat of 
control group; (B-L) tissures from rats by DEN-treated: (B) 
non-special injury of liver at the 6th week; (C) liver fibrosis at 
the 8th week; (D) liver cirrhosis at the 10th week; (E) liver cir-
rhosis rat at the 12th week; (F) dysplasia nodules at the 14th 
week; (G) liver carcinoma at the 16th week; (H) liver carci-
noma at the 20th week; (I) tumor embolism in blood vessel at 
the 20th week; (J) the metastasis mass in the abdormainal cav-
ity at the 20th week; (K) lung metastasis at the 20th week; (L) 
lung tissure of normal rat.
D
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Cellular proliferation, apoptosis, adhesion, migration and
agiogenesis all play important roles in carcinogenesis.
Extracellular matrix (ECM) is important for the growth
and progression of hepatocarcinogenesis (see additional
file 2 and Tables 3). There are 105 upregulated and 51
downregulated DEGs with the above functions.
The rat models of liver cancer induced by DEN occurred
following chronic injury, regenetation, fiborsis and cir-
rhosis. Elements of the inflammatory response, immune
response and oxidative stress were also involved in the
process of hepatocarcinogenesis. Tables 4 and 5 show that
the expression of 40 such genes was upregulated and the
expression of 27 genes was downregulated.
Hierarchy cluster analysis of DEGs
The DEGs commonly present from stages of cirrhosis to
metastasis were clustered by Cluster software according to
the values of log2 ratio(Figure 5A,B,C). The upregulated
(red) and the downregulated (green) DEGs had the same
alterated tendency during the process from liver cirrhosis
to metastasis. Furthermore, the DEGs involved in the
metabolism of glucose, lipids and alcohol and so on (Fig-
ure 6A), DEGs associated with the metabolism of glutath-
ione (Figure 6B) and DEGs of members belong to the
CYPs family were listed (Figure 6C).
Validation of differential expression of genes by real-time 
RT-PCR
The DEGs detected through Affymetrix genechip analysis
were confirmed in the selected tissue of DEN-treated and
control rats by real-time RT-PCR, as shown in Figure 7.
TWEAKR, ANXA2, CTGF were chosen from the upregu-
lated DEGs, and EGFR, KDR, CXCL12 were chosen from
the downregulated DEGs. The primer sequences for each
gene were listed in Table 6. The quality and specificity of
the amplified products were confirmed by visualization
on a 2% agarose gel. The results confirmed the validity of
the Affymetrix genechip results. The lower the ΔCt value
of the target gene, the more mRNA content of the target
gene there is in the tissue. The Ct value of β-actin obtained
from DEN-treated and normal tissue was almost identical.
Discussion
Some major drawbacks limit the usefulness of studies
regarding molecular pathogenesis in HCC. First, few stud-
ies analyze the genetic and genomic alterations that
emerge at different time points during the entire progres-
sive process of the disease. Second, the limited size of the
studies is often a factor that undermines the capability to
provide consistent genomic data[9]. Animal models of
hepatocarcinogenesis summarize the primal biology of
liver tumorigenesis and have provided reliable data for
understanding the cellular development of HCC in
humans[1,10,11]. In the present study, the pathologic
changes of livers in rats treated by DEN included non-spe-
cific injuries, regeneration and repair, fibrosis, and cirrho-
sis, dysplastic nodules, early tumorous nodules, advanced
tumorous nodules and metastasis foci, resembling the
process of human hepatocarcinogenesis. DEGs obtained
by compare normal rats with DEN-treated animals at
stages from cirrhosis to metastasis allowed us to screen for
upregulated and downregulated gene expressional pro-
files. The number of DEGs at each stage was large and the
information obtained was powerful. We were thus able to
visualize the complicated process of hepatocarcinogenesis
at the genomic level.
The annotated information of the DEGs show that exten-
sive and diverse biological processes and molecular func-
tions are involved in hepatocaricnogenesis. Most of the
DEGs are involved in metabolism and transport, indicat-
ing that significant alterations occurred in the process of
metabolism and transport during the developmnet of
HCC. For example, tumor cells always perform anaerobic
glycolysis, even when there is an adequate oxygen sup-
ply[12,13], partly a result of alterations in the profile of
enzymes associated with glycolysis. In this study, the gene
expression level of lactate dehydrogenase B increased
from the cirrhosis phase to the metastasis phase. Evidence
shows that some genetic changes promoting tumor
growth influences glucose energy metabolism
directly[14,15]. Many intermediate products from glycol-
ysis are used to synthesize proteins, nucleic acids and lip-
ids by tumor cells, providing the essential materials for the
growth and hyperplasia of tumor cells. For aggressive
Total RNA isolated from the liver tissues of the rats was  identified by agar electrophoresis Figure 3
Total RNA isolated from the liver tissues of the rats 
was identified by agar electrophoresis. (A) from normal 
rats; (B-E) from DEN-treated rats: cirrhosis tissue at 12th 
week (B), dysplastic nodules at the 14th week (C), early can-
cerous nodules at the 16th week (D), cancerous nodules with 
lung metastasis at the 20th week (E).
B
A       B       C        D       E  Journal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
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tumors, increased glycolysis and metabolism alterations
often occurred. The microenvironment acidosis provided
by the conversion of pyruvic acid to lactic acid promotes
invasion and metastasis of tumor cells [16-18]. Therapy
targeting glycolysis could preferentially kill tumor cells
with metabolic alterations and there is experimental evi-
dence that some types of tumors can be treated by inhib-
iting the glycolytic and phosphopentose pathways[16]. In
this study, some DEGs associated with metabolisms of
glucose were shown in Figure 6A.
Fat metabolism have significant changes in the process of
tumorigenesis, e.g. a high fat diet was related to the devel-
opment of many tumors [19]. Enhanced fat synthesis in
tumor cells could not only support the increased mem-
brane synthesis and energy metabolism, but also higher
level of fatty acid synthetase provides the base for interpre-
tation the relation between the fat metabolism and the
capacity of hyperplasia and metastasis of tumor cells[20].
Stearoyl-CoA desaturase (SCD), which have four known
isomers, takes part in regulating lipid synthesis. SCD2
plays key roles in the early development and survival of
embryos in mice, whose expressional levels in the livers of
wild mice embryos and newborn mice were higher than
that of adult mice[21]. Inhibition of lipid synthesis caused
by the depletion of SCD2 was related to the decreased
Scatter plot of gene expression comparisons between the normal rats and DEN-exposured rats Figure 4
Scatter plot of gene expression comparisons between the normal rats and DEN-exposured rats. Each point rep-
resents a single gene or EST. x-axis: control (from liver tissue of normal rat); y-axis: liver tissue from DEN- treated rat at 12th 
week (A); at 14th week (B); at 16th week (C); at 20th week (D). The red points represent 'present' states both in control and 
DEN exposed; blue points represent 'no present' in either of control and DEN-exposed; yellow points represent 'absent' 
states both in control and DEN-exposed.
B
C
A
D
Table 1: Number of differential expression genes (DEGs) of liver tissues from DEN-treated rats compared with control.
DEGs 12th week 14th week 16th week 20th week
Up-regulated DEGs 681 857 1223 999
Down-regulated DEGs 687 732 1016 906
Total 1368 1589 2239 1905
NOTE: The words '12th week, 14th week, 16th week, 20th week' in the table indicate the cirrhosis tissue, dysplastic nodules, early cancerous nodules 
and cancerous nodules with metastasis, respectively.Journal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
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expression level of peroxisome proliferator-activated
receptor gamma (PPAR-γ)[22]. Fatty acid binding proteins
(FABPs) are proteins that could bind to fatty acid and
other lipids reversibly. Researchers found expression of
FABP5, coding epidermal fatty acid binding protein (E-
FABP-GenBank Accession), upregulated in primary
tongue carcinomas[23]. FABP4, as a bridge between the
inflammation and other metabolism syndromes[24],
could not only transport the nuclear receptor PPAR-γ from
cytoplasm to nucleus but also cause increased transcript
activation of it[25]. In this study, the expressional levels of
SCD2, FABP4 and FABP5 increased during the process
from cirrhosis to metastasis in rat model, suggesting that
an alteration of the fat metabolism occurred in hepatocar-
cinogenesis of rat model. Other DEGs associated with
fatty metabolisms were shown in Figure 6A.
In the present study, some enzymes related to the glutath-
ione (GSH) metabolism were found to be significantly
altered. For example, the expressional level of Gstm3 (glu-
tathione S-transferase, mu type 3) decreased in all stages
of hepatocarcinogenesis, while the expression levels of of
enzymes increased, which including Glul (Glutamate-
ammonia ligase), Gclc (Glutamate-cysteine ligase, cata-
lytic subunit), GPX2 (Glutathione peroxidase 2), GPX3
(Glutathioneperoxidase 3), GSR (Glutathione reductase),
Yc2 (Glutathione S-transferase Yc2 subunit), Gstm5 (Glu-
tathione S-transferase, mu 5), Gstp1 (Glutathione-S-
transferase, pi 1) and GSS (Glutathione synthetase). Some
studies reported that GSH and the associated enzymes
were considered to promot the tumor transformation
from dysplastic nodules and take part in the development
and progression of hepatocarcinomas[26,27]. In gastro-
enteric tumors, the increase of GSH and the associated
enzymes exhibit activation, indicating the existence of
ROS and anti-oxidation defense related to GSH metabo-
lism[28]. There were five binding sites for β-catenin/TCF
at the promoter region of GPX2, indicating that GPX2
might take part in the corresponding signal pathways[29].
Thus previous research and our data indicate that genes
related to oxidative stress and GSH metabolism play
important roles in the process of progression from dys-
plastic nodules to tumor. The expressional level of GSH
increased in tissue of HCC and the active hyperplasia liver
cells[30,31]. Research has shown that DNA oxidative
injury is increased in human HCC [32,33].
Many other enzymes associated with metabolism are
involved in the defense and stress reaction, such as oxida-
tive stress. For example, AKR1B7 (aldo-keto reductase
family 1, member 7) takes part in the detoxification of
oxides, such as aldehyde. During the detoxification of
aldehyde, the expressional level of AKR1B7 mRNA
increased. There are five binding sites with NF-κB at the 5'
upstream region of the AKR1B7 gene, and oxidative stress
upregulates the expression of AKR1B7 mediated by NF-
κB[34,35]. The expression level of aldehyde dehydroge-
nase ALDH3A1 (Aldehyde dehydrogenase 3A1) also
increased after oxidative stress. In the present study, the
expression levels of AKR1B7, AKR1B8 and ALDH3A1 were
up-regulated at all stages of hepatocarcinogenesis. In the
tumor cells, reactive oxigen species (ROS) was produced
Table 2: The deregulated DEGs sharing from cirrhosis to metastasis stage classified by the following screened GO.
Functional Categories Number Of Annotated Genes
12th week 14th week 16th week 20th week 4 group
Metabolism 334/318 403/324 541/446 494/375 206/198
Transport 162/164 188/167 264/225 229/195 101/106
Cell Growth 129/88 161/86 207/104 218/88 89/51
Cell Differentiation 103/57 127/67 170/69 171/69 72/35
Apoptosis 87/50 113/48 128/62 153/46 59/28
Angiogenesis 12/11 15/13 23/15 25/14 9/6
Cell Proliferation 68/51 93/57 108/57 115/54 46/36
Cell Migration 13/12 15/15 30/13 25/13 10/8
Cell Adhesion 62/25 76/30 106/30 94/30 40/13
Extracellular Matrix 41/21 48/22 61/29 73/23 26/14
Oxidative Stress 31/19 41/24 43/27 50/26 23/12
Immune Response 30/25 34/23 38/35 35/28 19/16
Inflammatory Response 12/17 18/20 17/31 18/21 7/11
Cytochrome 19/30 23/28 29/45 25/38 11/20
Signal Transduction 140/106 165/111 243/129 213/115 87/59
Protein Kinase 114/67 128/77 193/95 185/73 65/38
Proteasome 17/6 20/8 25/7 19/6 13/4
NOTE: The words '12th week, 14th week, 16th week, 20th week' in the table indicate the cirrhosis tissue, dysplastic nodules, early cancerous nodules 
and cancerous nodules with metastasis, respectively. The word '4 group' means the DEGs sharing for the above 4 stages of liver tissues. The 
numbers up and down the line indicate the number of up-regulated and down-regulated DEGs respectively.Journal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
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through the oxidative stress. ROS as signal molecules
mediate various reactions relating to growth, such as ang-
iogenesis. ROS in endothelial cells is mainly from
NADPH oxidation enzymes, consisting of Nox1, Nox2,
Nox4, Nox5, p22 (phox), p47 (phox) and Rac1 (small G-
protein Rac1). NADPH oxidative enzymes were activated
by different factors including VEGF, angiopoietin-1,
hypoxia and ischemia. Furthermore, ROS has been shown
to be involved in spontaneous phosphorylation[36].
Nox4 mediated growth factors, such as anti-apoptosis of
Table 3: The down-regulated DEGs sharing from cirrhosis to metastasis sorted out by the following GO function.
Gene Symbol Gene Title GO
COL18A1 procollagen, type XVIII, alpha 1 1–6
CXCL12 chemokine (C-X-C motif) ligand 12 1,2,4,5
KDR kinase insert domain protein receptor 1,4,6
SERPINA3K serine (or cysteine) peptidase inhibitor, clade A, member 3K 1,2,5
ANG1 angiogenin, ribonuclease A family, member 1 1,5
RNASE4 ribonuclease, RNase A family 4 1,5
C5 complement component 5 2,4
CML4 Camello-like 4 3
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 3
GPHN gephyrin 3
IGFALS insulin-like growth factor binding protein, acid labile subunit 3
LIN7A lin-7 homolog a (C. elegans) 3
AZGP1 alpha-2-glycoprotein 1, zinc 3,5
PROC Protein C 2
PTPRD protein tyrosine phosphatase, receptor type, D 3
PVRL3_predicted poliovirus receptor-related 3 (predicted) 3
SORL1 sortilin-related receptor, LDLR class A repeats-containing 4,5
TGFBI transforming growth factor, beta induced 3,4,6
RB1 retinoblastoma 1 2,3,5
EGFR epidermal growth factor receptor 2–6
EGF epidermal growth factor 2,5,6
IGF1 Insulin-like growth factor 1 2,5,6
HNF4A Hepatocyte nuclear factor 4, alpha 2,5
BCL6_PREDICTED B-cell leukemia 6 (predicted) 2,5
PEMT phosphatidylethanolamine N-methyltransferase 2,5
LRP1 low density lipoprotein receptor-related protein 1 2,5
RGN regucalcin 2,5
SGPP1 sphingosine-1-phosphate phosphatase 1 2
NR1D2 nuclear receptor subfamily 1, group D, member 2 2
GHR Growth hormone receptor 2
CYP2E1 cytochrome P450, family 2, subfamily e, polypeptide 1 2
C4BPB complement component 4 binding protein, beta 2
C6 complement component 6 2
FAAH fatty acid amide hydrolase 2
NR0B2 nuclear receptor subfamily 0, group B, member 2 2
PCSK9 proprotein convertase subtilisin/kexin type 9 2
UNG uracil-DNA glycosylase 2
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 5
PCAF p300/CBP-associated factor 5
CFB complement factor B 5
DBP D site albumin promoter binding protein 5
ADRA1B adrenergic receptor, alpha 1b 5
FABP1 fatty acid binding protein 1, liver 5
VIPR1 vasoactive intestinal peptide receptor 1 5
ID4 Inhibitor of DNA binding 4 5
NOX4 NADPH oxidase 4 5
AMY1 amylase 1, salivary 6
GPLD1 glycosylphosphatidylinositol specific phospholipase D1 6
SMOC1 SPARC-related modular calcium binding protein 1 6
NOTE: The numbers from 1–6 indicate GO terms: angiogenesis, apoptosis, cell adhesion, cell migration, cell proliferation and extracellular matrix, 
respectively.Journal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
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IGF, is partly due to the ROS produced by NADPH oxida-
tive enzymes inhibiting the key protein tyrosine phos-
phatases(PTPs), then continually causing JAK2 kinase
phosphorylation which resists the apoptosis reaction[37].
In this study, However, the gene expression level of
NADPH oxidative enzymes decreased in the livers of our
rat model at all stages of hepatocarcinogenesis. The mech-
anism is unclear.
Cytochrome P450s (CYPs) are key enzymes in tumorigen-
esis, taking part in the activation and inactivation of
chemotherapeutic agents in tumor tissues[38]. The
expression level of CYP1B1 in breast carcinomas was up-
regulated significantly, providing a new therapy target and
phenotype biomarker. The significant increase in CYP2E1
correlates with invasiveness and is a potential prognosis
factor[39,40]. Other studies have shown that the expres-
sion of CYP could influence the synthesis of arachidonic
acid derivatives, thus altering the various downstream sig-
nal pathways, which was thought to be the prelude of car-
cinogenesis[41]. At present, it is not possible to always
predict the efficacy of a chemotherapeutic agent or its
degree of toxicity. Analysis of CYPs expressional levels in
tumor cells may allow prognosis decisions and therapy
predictions. In this study, only the expression level of
CYP2C40 increased at all stages of hepatocarcinogenesis
Table 4: The up-regulated DEGs sharing from cirrhosis to metastasis stage relating to the following GO process.
Gene symbol Gene name GO
CCL21B chemokine (C-C motif) ligand 21b (serine) 1–2
CD276 CD276 antigen 1–2
SPP1 secreted phosphoprotein 1 1–2
CD24 CD24 antigen 1
C1QG complement component 1, q subcomponent, gamma polypeptide 1
CD74 CD74 antigen 1
HLA-DMA major histocompatibility complex, class II, DM alpha 1
HLA-DMB major histocompatibility complex, class II, DM beta 1
DEFB1 defensin beta 1 1
FCGR3 Fc receptor, IgG, low affinity III 1
PLSCR1 phospholipid scramblase 1 1
PRNP prion protein 1
RT1-BA RT1 class II, locus Ba 1
RT1-CE5 RT1 class I, CE5 1
RT1-DA RT1 class II, locus Da 1
RT1-DB1 RT1 class II, locus Db1 1
RT1-BB RT1 class II, locus Bb 1
ANXA1 annexin A1 2
FABP4 fatty acid binding protein 4, adipocyte 2
S100A8 S100 calcium binding protein A8 2
S100A9 S100 calcium binding protein A9 2
CDC2A cell division cycle 2 homolog A 3
EGR1 early growth response 1 3
CRYAB crystallin, alpha B 3
CCND1 cyclin D1 3
CD36 cd36 antigen 3
GCLC glutamate-cysteine ligase, catalytic subunit 3
GGT1 gamma-glutamyltransferase 1 3
GPX2 glutathione peroxidase 2 3
GPX3 glutathione peroxidase 3 3
GSR glutathione reductase 3
GSS glutathione synthetase 3
HSPCB heat shock 90 kDa protein 1, beta 3
LAMC1 laminin, gamma 1 3
MTAP2 microtubule-associated protein 2 3
NOL3 nucleolar protein 3 (apoptosis repressor with CARD domain) 3
NQO1 NAD(P)H dehydrogenase, quinone 1 3
PDLIM1 PDZ and LIM domain 1 (elfin) 3
SLC25A4 solute carrier family 25 3
TXNRD1 thioredoxin reductase 1 3
NOTE: The numbers from 1–3 indicate immune response, inflammatory response and oxidative stress, respectively.Journal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
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in rat models, while the remaining CYPs decreased (Figure
6C). Clearly, further investigation is needed to determine
the role(s) of CYPs in hepatocarcinogenesis.
In addition to the deregulated expression of metabolism
associated genes, we noticed that among the DEGs in the
hepatocarcinogenesis of rat models, some known tumor-
associated genes, such as Rb1 and Myc, showed deregu-
lated expression occurring at all the stages of hepatocar-
cinogenesis. Their persisting activation or deactivation
could induce the tumor phenotype, as well as play roles at
the later stage of progression and metastasis. Meanwhile,
some known metastasis-associated genes are found dereg-
ulated at the promotion stage of tumor development. For
example, the expression level of Ndrg2 and Hrasls3
(HRAS like suppressor 3) decreased at all stages compared
to the normal livers, while the expression level of Nme1
(expressed in non-metastatic cells 1) increased. Generally,
it was thought that genes involved in the development of
carcinoma activation participated at the early stage, while
genes participating in the metastasis were activated at the
latter stage of tumor progression[42]. In opposition to the
traditional model, Bernards and Weinberg proposed that
the metastatic ability of tumor cells occurred at the early
stage of tumor development[43]. Some oncogenes such as
Ras and Src assigned the tumor cells with the metastatic
phenotype [44-46].
As we known, the important characteristic of malignant
tumor cells is the capability of invading the vicinity, form-
ing metastasis foci at the remote organ, overcoming the
host's control over the microenvironment[47,48]. The
malignant transformation of liver cells occurred on the
basis of chronic injury, regeneration and cirrhosis. The
liver cancer cells could synthesize ECM components and
the ECM surrounding liver cancer cells was found to be
different from that of stroma in the normal organ [49-51].
Integrin and laminin are the major components of ECM.
The interaction between integrin and laminin is closely
related to the signal transduction, providing survival sig-
nals for the cells, mediating the liver cancer cells forma-
tion of pseudopodia, and adherence with laminin, which
are imperative if a liver cancer cell is to migrate and invade
[52-55]. In the process of hepatocarcinogenesis in this rat
model, the deregulated expression of many ECM associ-
ated genes plays important roles in the hepatocarcinogen-
esis, e.g. Itga6, Lamc1, Col1a1 and Spp1, etc. (Table 2, 3
and additonal file 2). The differential expression profile of
ECM associated genes in time course and space is very
important to cellular proliferation and migration.
Table 5: The down-regulated DEGs sharing from cirrhosis to metastasis stage relating to the following GO process.
Gene Symbol Gene Title GO
C5 complement component 5 1–2
IL4RA interleukin 4 receptor, alpha 1–2
MBL2 mannose binding lectin 2 (protein C) 1–3
NOX4 NADPH oxidase 4 2–3
ATRN Attractin 2–3
C1S complement component 1, s subcomponent 1
C4BPB complement component 4 binding protein, beta 1
AZGP1 alpha-2-glycoprotein 1, zinc 1
C6 complement component 6 1
CXCL12 chemokine (C-X-C motif) ligand 12 1
MX2 myxovirus (influenza virus) resistance 2 1
OAS1 2',5'-oligoadenylate synthetase 1, 40/46 kDa 1
RT1-S3 RT1 class Ib, locus S3 1
VIPR1 vasoactive intestinal peptide receptor 1 1
APOA2 apolipoprotein A-II 2
BCL6_predicted B-cell leukemia/lymphoma 6 (predicted) 2
KLKB1 kallikrein B, plasma 1 2
PROC protein C 2
PTGER3 Prostaglandin E receptor 3 (subtype EP3) 2
MEOX2 mesenchyme homeobox 2 3
CA3 carbonic anhydrase 3 3
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 3
ALAD aminolevulinate, delta-, dehydratase 3
CYP2E1 cytochrome P450, family 2, subfamily e, polypeptide 1 3
EGFR epidermal growth factor receptor 3
HAO1 hydroxyacid oxidase 1 3
HNF4A Hepatocyte nuclear factor 4, alpha 3
NOTE: The numbers from 1–3 indicate immune reponse, inflammatory response and oxidative stress, respectively.Journal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
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Hierarchial clustering of screened differential expressional genes Figure 5
Hierarchial clustering of screened differential expressional genes. (A) hierarchical clustering of 694 deregulated genes 
shared in liver tissues of DEN-treated rats from cirrhosis tissues at the 12th week, dysplastic nodules at the 14th week, early 
cancerous nodules at the 16th week, and cancerous nodules with lung metastasis at the 20th week, respectively. (Red, a high 
expression level as compared with the mean; green, a low expression level as compared with the mean). (B) the dendrogram of 
the 246 upregulated known genes shared in the liver tissues of four chips is magnified. (C)the dendrogram of the 215 downreg-
ulated known genes shared in the liver tissues of four chips is magnified.
A
B
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It is worthy of note that the expression of the annexin fam-
ily members and calcium-binding proteins are deregu-
lated in this rat model of liver cancer. In our study, the
expressional level of Annexin A1, A2, A3, A5 and A7
increased compared with the normal liver tissue. Annex-
ins consist of a conserved protein family. Annexin A2 is
closely associated with cell division regulation and tumor
growth, and is deregulated in many tumors[56,57]. Two
Annexin A2 molecules bind to the long chains of p11/
S100A10 dimers through its N-terminals, form the isote-
tramer, regulating the reactions of Annexin A2 and mem-
branes and actin in cortical areas, and the distribution of
recirculating endosomes[58]. In addition, S100A10 and
Annexin A2 form isodimers, prompting the invasion and
metastasis of the tumor by activating plasminogen[59]. In
the present study, the expression level of S100a10,
S100a11, S100a6, S100a8 and S100a9 increased from cir-
rhosis to metastatic process when compared with the nor-
mal liver. S100A8/A9 form the compounds that play a
role in inducing apoptosis in tumor cells. S100A8/A9 at
low concentrations prompts growth activity, the phos-
phorylation of MAPK pathway and NF-κB is activated in
cells after S100A8/A9 treatment.
The majority of HCCs slowly unfold against a background
of chronic hepatitis and cirrhosis, which can be consid-
Hierarchial clustering of deregulated genes involved in appointed functions Figure 6
Hierarchial clustering of deregulated genes involved in appointed functions. (A) hierarchical clustering of deregu-
lated genes involved in metabolism such as glucose, fat, alcohol and so on. (B) hierarchical clustering of 25 genes whose expres-
sion was significantly correlated with metabolism of glutathione. (C) all of the cytochrome P450 members deregulated shared 
in liver tissues of DEN-treated rats from the cirrhosis tissues at the 12th week to the metastasis phase at the 20th week.
A
B
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ered as preneoplastic conditions of the liver. Chronic hep-
atitis is characterized by persistent inflammation,
cytokine and oxidative stress-mediated hepatocyte death
and active proliferation of residual hepatocytes to replace
the lost parenchyma[1,60]. During the process of hepato-
carcinogenesis in rat models, chronic inflammation pre-
cedes cirrhosis. Epidemiology studies showed that
chronic inflammation increased the risk of tumors, and
the microenvironment of tumorigenesis resembles the
reaction of inflammation to injury in many ways[61]. In
the tumor microenvironment, the chemotactic factors and
receptors mediated angiogenesis, recruited cells, prompt-
ing cellular survival and proliferation. On the other hand,
oxidative stress occurred in inflammatory processes. The
inflammatory cells and tumor cells both produce free rad-
icals and soluble factors such as arachidonic acid,
cytokines and chemotactic factors, seubsequently produc-
ing reactive oxygen. All these factors strongly recruit the
inflammatory cells to produce cytokines, which promotes
a vicious cycle. The intermediate products of active oxygen
oxidize DNA directly or interfere with DNA repair. These
oxides activate protein, carbohydrate and lipids quickly,
the derived products interfere with inter- and intracellular
homeostasis, favoring DNA mutation. Thus, the chronic
inflammation prompts the malignant transformation of
cells[62]. Chronic inflammation also favors angiogen-
esis[63]. In the present study, many DEGs are related to
inflammation reaction, immune reaction and stress.
(Tables 4 and 5)
Conclusion
In conclusion, analysis of gene expression profile is a use-
ful tool to provide new clues and produce new research
targets in the hepatocarcinogenesis field. In the present
study, a rat model of liver cancer was established. We have
listed the deregulated expression genes in the process
from cirrhosis to liver cancer in the DEN-treated rat
model. As indicated in the literature, this model shows
that cirrhosis is a precancerous lesion of the liver.
Although we only discuss some parts of the great quantity
of information in this study, much unknown information
remains. Functional analysis of these genes revealed dis-
crete expression clusters, including cell proliferation, pro-
tein synthesis, and hepatocyte-specific functions. We still
need to discern the key genes playing core roles in the pro-
motion and progression of liver cancer. In this article, we
focused our attention on the global molecular events that
occurred in DEN-treated rats (and probably represent the
earliest ones that start the multistep process of hepatocar-
cinogenesis). Additional information may be mined from
this and similar studies to provide clues to many areas
including the very important search for diagnostic mark-
ers, therapy targets and prognosis prediction markers.
Histogram of Ntarget value of the genes for validation by real  time RT-PCR Figure 7
Histogram of Ntarget value of the genes for valida-
tion by real time RT-PCR. Each collumn represents Ntar-
get value of the corresponding target gene in cirrhosis tissues 
at the 12th week, dysplastic nodules at the 14th week, early 
cancerous nodules at the 16th week and cancerous nodules 
with lung metastasis at the 20th week.
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Table 6: Primer sequences.
Primer name Sequence Product size (bp)
TWEAKR forward 5' GTGTTGGGATTCGGGTTGGTG 3' 221
TWEAKR reverse 5' CTAAGAGCGCCTCCCAGAATGG3'
ARHGAP24 forward 5' TAGCATCAACTCCTTTCATCCC3' 232
ARHGAP24 reverse 5' TCCTTGACAAGGTTTGCCTG3'
RTN4 forward 5' TGGTGGTTCTGTGCGGTGTG3' 248
RTN4 reverse 5' AGCTGTCCTTCACAGGTTC3'
KDR forward 5'TTTCTGCTCCTTGGTCCTGG3' 222
KDR reverse 5' TGTCGCCACACTCAGTCAC 3'
EGFR forward 5' CCTTAGCCGTCCTGTCCAAC 3' 235
EGFR reverse 5' TTGGGACAGCTCGGATCAC 3'
CXCL12 forward 5' CCCTGCCGATTCTTTGAG3' 175
CXCL12 reverse 5' TGTTTAAGGCTTTGTCCAGG3'
Beta-actin forward 5' AGGGTGTGATGGTGGGTATGGG 3' 230
Beta-actin reverse 5' TTCACGGTTGGCCTTAGGGTTC 3'Journal of Experimental & Clinical Cancer Research 2009, 28:107 http://www.jeccr.com/content/28/1/107
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